Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.21.1
Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 01, 2021
Jul. 22, 2016
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 04, 2020
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock, shares authorized     125,000,000   125,000,000    
Common stock par value (in dollars per share)     $ 0.0001   $ 0.0001    
Preferred stock, shares authorized     2,000,000   2,000,000    
Aggregate value of shares subscribed     $ 218   $ 7,939    
Common stock, shares issued     85,043,153   70,920,693    
Common stock, shares issuable     63,688   2,103,122    
Shares available for future sale     203,181        
Proceeds from employee stock purchase plan     $ 200        
Fortress Biotech, Inc [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Percentage of fully diluted equity 2.50% 2.50%   2.50%      
Expenses from related party transaction     $ 100 $ 100      
Issuance of common shares (in shares)     325,221 31,220      
Shares issued, price per share     $ 4.16 $ 4.00      
Proceeds from issuance of common shares - Public Offering       $ 48,400      
At the Market Offering [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Agent commission (as a percent)             3.00%
Issuance of common shares (in shares)     11,600,000 1,200,000      
Shares issued, price per share     $ 4.17 $ 3.93      
Proceeds from issuance of common shares - Public Offering     $ 48,400 $ 5,000      
Proceeds from issuance of Common Stock, net of offering costs     47,500 4,900      
Aggregate fees of stock issuance     $ 900 $ 100      
At the Market Offering [Member] | Fortress Biotech, Inc [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock, shares issuable     63,688        
Registration Statements [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Sale of Stock aggregate offering price permitted by agreement           $ 100,000 $ 75,000
Common stock shares available for future issuance     $ 37,800        
Class A Common Shares [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock, shares issued     845,385   845,385    
Preferred Class A [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Preferred stock, shares issued     250,000   250,000    
General and Administrative [Member] | Fortress Biotech, Inc [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expenses from related party transaction     $ 1,200